{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:46:33Z","timestamp":1782513993561,"version":"3.54.5"},"reference-count":72,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Obstet Med"],"abstract":"<jats:p>Eplerenone is a mineralocorticoid receptor antagonist with minimal affinity for androgen receptors. Mineralocorticoid receptor antagonists are efficacious in the management of resistant hypertension, obstructive sleep apnea, cardiac dysfunction, renal tubular disorders, hepatic cirrhosis, portal hypertension, diabetic nephropathy, proteinuric kidney disease, and chronic central serous chorioretinopathy in the general population. Five cases describing the use of eplerenone in pregnancy are discussed, the previous literature reviewed, and potential indications for the use of eplerenone in pregnancy discussed.<\/jats:p>","DOI":"10.1177\/1753495x261463148","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:19:30Z","timestamp":1782310770000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Eplerenone in pregnancy"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9887-714X","authenticated-orcid":false,"given":"Adam","family":"Morton","sequence":"first","affiliation":[{"name":"Mater Hospital Brisbane"},{"name":"University of Queensland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1530\/acta.0.0950540"},{"key":"e_1_3_2_3_2","first-page":"347","article-title":"Experimental study on teratology of spironolactone","volume":"24","author":"Seassaro E","year":"1969","unstructured":"Seassaro E, Pellegrini R. Experimental study on teratology of spironolactone. Quad Clin Ostet Ginecol 1969; 24: 347\u2013358.","journal-title":"Quad Clin Ostet Ginecol"},{"key":"e_1_3_2_4_2","first-page":"95","article-title":"Lack of effect of spironolactone on male genital development","volume":"13","author":"Rose LI","year":"1975","unstructured":"Rose LI, Regestein Q, Reckler JM. Lack of effect of spironolactone on male genital development. Invest Urol 1975; 13: 95\u201396.","journal-title":"Invest Urol"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","unstructured":"Shah A. Ambiguous genitalia in a newborn with spironolactone exposure [abstract]. In: 93rd Annual Meeting of the Endocrine Society Boston June 6 2011.","DOI":"10.1210\/endo-meetings.2011.PART3.P27.P3-227"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2002.01430.x"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(95)90549-9"},{"key":"e_1_3_2_8_2","first-page":"489","article-title":"Idiopathic aldosteronism in pregnancy","volume":"78","author":"Neerhof MG","year":"1991","unstructured":"Neerhof MG, Shlossman PA, Poll DS, et al. Idiopathic aldosteronism in pregnancy. Obstet Gynecol 1991; 78: 489\u2013491.","journal-title":"Obstet Gynecol"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-009-0994-3"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(96)70418-0"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1404251"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.1673-23"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/1753495X241241833"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12884-020-03117-1"},{"key":"e_1_3_2_15_2","first-page":"421","article-title":"Gitelman syndrome in pregnancy\u2014a severe hypokalemia with favorable perinatal prognosis","volume":"77","author":"Rusavy Z","year":"2012","unstructured":"Rusavy Z, Hudec A, Karbanova J, et al. Gitelman syndrome in pregnancy\u2014a severe hypokalemia with favorable perinatal prognosis. Ceska Gynekol 2012; 77: 421\u2013423.","journal-title":"Ceska Gynekol"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-012-0154-8"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.20324"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2016.1878"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.3410"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-025-05098-5"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-025-01356-1"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf290"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-021-00621-5"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","unstructured":"Kanan M Alshahrani R Alqahtani A et al. Exploring the clinical pharmackinetics of eplerenone: A systematic review of Pharmacy Practice(2025).","DOI":"10.18549\/PharmPract.2025.2.3127"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2026.2656561"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1797.2010.01396.x"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198020010-00005"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(72)90175-0"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(72)90036-1"},{"key":"e_1_3_2_30_2","first-page":"300","article-title":"A comparison of alpha-methyldopa (aldomet) and ST155 (catapres) in the treatment of hypertension","volume":"44","author":"Seedat YK","year":"1970","unstructured":"Seedat YK, Vawda EI, Mitha S, et al. A comparison of alpha-methyldopa (aldomet) and ST155 (catapres) in the treatment of hypertension. S Afr Med J 1970; 44: 300\u2013301.","journal-title":"S Afr Med J"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.4.5732.392"},{"key":"e_1_3_2_32_2","first-page":"18","article-title":"Antihypertensive effect of prazosin in combination with methyldopa, clonidine, or propranolol","volume":"11","author":"Kuokkanen K","year":"1979","unstructured":"Kuokkanen K, Mattila MJ. Antihypertensive effect of prazosin in combination with methyldopa, clonidine, or propranolol. Ann Clin Res 1979; 11: 18\u201324.","journal-title":"Ann Clin Res"},{"key":"e_1_3_2_33_2","first-page":"904","article-title":"Three drugs and still hypertensive: what\u2019s left?","volume":"62","author":"Turgeon R","year":"2016","unstructured":"Turgeon R, Garrison S, Allan GM. Three drugs and still hypertensive: what\u2019s left? Can Fam Physician 2016; 62: 904.","journal-title":"Can Fam Physician"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2009.96"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.3109\/10641963.2015.1131290"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8101671"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11325-024-03113-1"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf193"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-5299.2005.05316.x"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfs126"},{"key":"e_1_3_2_41_2","first-page":"30","article-title":"Proximal weakness and hypokalemia in a pregnant woman: the first presentation of gitelman syndrome","volume":"5","author":"Najafi MSP","year":"2020","unstructured":"Najafi MSP, Naderi N. Proximal weakness and hypokalemia in a pregnant woman: the first presentation of gitelman syndrome. Case Reports in Clinical Practice 2020; 5: 30\u201334.","journal-title":"Case Reports in Clinical Practice"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-241756"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preghy.2016.12.001"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1177\/1753495X19825967"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.187237"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.355"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000914220.62267.70"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1177\/1753495X231160322"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2024-262767"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preghy.2024.101157"},{"key":"e_1_3_2_51_2","article-title":"Multi-modal treatment in a pregnant woman with untreated cardiac sarcoidosis complicated by cardiac dysfunction and ventricular arrhythmias: a case report and literature review","volume":"8","author":"Yoshii T","year":"2024","unstructured":"Yoshii T, Kanzaki H, Aoki-Kamiya C, et al. Multi-modal treatment in a pregnant woman with untreated cardiac sarcoidosis complicated by cardiac dysfunction and ventricular arrhythmias: a case report and literature review. Eur Heart J Case Rep 2024; 8: ytae108.","journal-title":"Eur Heart J Case Rep"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2025.100429"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac311"},{"key":"e_1_3_2_54_2","unstructured":"Lopez DRL Maningat-Goco M. Use of eplerenone in primary aldosteronism during pregnancy: a case series. In: 22nd ASEAN Federation of Endocrine Societies Congress Bangkok Thailand 16-19th November 2023 2023 pp.1-1."},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.121.18858"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf284"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-0631"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13419"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014030293"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-01259-w"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1080\/14767058.2023.2253956"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.870503"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13081862"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf116.0914"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2008.44.12.1131826"},{"key":"e_1_3_2_66_2","first-page":"1","article-title":"Intravenous ferric carboxymaltose in patients with heart failure and iron deficiency: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis","volume":"13","author":"Ahmed M","year":"2026","unstructured":"Ahmed M, Zulfiqar E, Hashmi TM, et al. Intravenous ferric carboxymaltose in patients with heart failure and iron deficiency: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. ESC Heart Fail 2026; 13: 1\u201313. DOI:https:\/\/doi.org\/10.1093\/eschf\/xvaf018.","journal-title":"ESC Heart Fail"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.5455\/medarh.2023.77.105-111"},{"key":"e_1_3_2_68_2","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"145","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation 2022; 145: e876\u2013e894.","journal-title":"Circulation"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.12270"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000004200"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202718"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000001805"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.05.007"}],"container-title":["Obstetric Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753495X261463148","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1753495X261463148","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753495X261463148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T21:47:51Z","timestamp":1782510471000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1753495X261463148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":72,"alternative-id":["10.1177\/1753495X261463148"],"URL":"https:\/\/doi.org\/10.1177\/1753495x261463148","relation":{},"ISSN":["1753-495X","1753-4968"],"issn-type":[{"value":"1753-495X","type":"print"},{"value":"1753-4968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"article-number":"1753495X261463148"}}